All In Biotech

Drug Trial Radar · NCT02406989

A Multiple-Ascending Dose Study of MS-553 in Healthy Volunteers

A Randomized, Double-Blind, Placebo-Controlled, Phase 1, Multiple-Ascending Dose Study of MS-553 in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Mar 16, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Apr 2015

Primary completion

Aug 2015

Study completion Sep 2015

Sponsor

Sponsor type
Industry
First posted
Apr 2, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, multiple-ascending dose study of MS-553 in healthy volunteers. Endpoints are safety, tolerability, and pharmacokinetics. Subjects are dosed for 14 days.

Conditions

  • Safety and PK in Healthy Volunteers

Interventions

  • MS-553Drug

    Study Drug

  • PlaceboDrug

    Matching placebo to MS-553

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects with Adverse Events as a Measure of Safety and TolerabilityTime frame: 14 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.